SKU: C014

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

Cefpirome sulfate is a semisynthetic, broad-spectrum, fourth generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.  Cefpirome is a β-lactam antibiotic consisting of a β-lactam ring bound to a dihydrothiazine ring. This two-ring system distorts the β-lactam amide bond, resulting in increased reactivity.  Cefpirome sulfate is soluble in DMSO (1 mg/ml).

TOKU-E offers two forms of Cefpirome:

    CAS Number

    98753-19-6

    Molecular Formula

    C22H22N6O5S2H2SO4

    Molecular Weight

    612.66

    Mechanism of Action

    Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases.

    The relative lack of cross-resistance between Cefpirome and the third generation cephalosporins suggests a slightly different mechanism of action of Cefpirome in comparison to the other cephalosporins. Due to its compact dipolar structure, Cefpirome can penetrate Gram-negative bacteria more quickly than the other agents (Nikaido et al, 1990)

    Storage Conditions

    -20°C

    Tariff Code

    2941.90.3000

    Spectrum

    Cefpirome is a broad spectrum antibiotic targeting a wide variety of Gram-positive and Gram-negative bacteria. A relatively low affinity of Cefpirome for lactamases is considered to be one of the reasons for its high antimicrobial activity against such enzyme-producing strains (Nikaido et al, 1990). Many Bacteroides, Enterococci, and Haemophilus species have developed resistance to Cefpirome.

Applications

    Cancer Applications

    Cefpirome was found to be more effective than ceftazidime, aztreonam, timentin, and piperacillin against nosocomially important isolates from cancer patients during in vitro examination of 253 bacterial isolates (Rolston et al, 1986).

    Microbiology Applications

    Cefpirome sulfate is commonly used in clinical in vitromicrobiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against gram positive and gram negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:

    • Campylobacter jejuni 0.5µg/mL – 8 µg/mL
    • Klebsiella pneumoniae 0.032 µg/mL – 0.125 µg/mL
    • For a complete list of cefpirome MIC values, click here.

Specifications

    Form

    Powder

    Appearance

    White or almost white crystalline powder

    Source

    Synthetic

    Water Content (Karl Fischer)

    ≤4.0%

    pH

    (2% in H2O): 1.3-2.5

    Assay

    ≥99.0% (on dried basis)

    Residue On Ignition

    ≤0.1%

    Heavy Metals

    ≤20ppm

    Impurities

    Single Impurity: ≤0.2%
    Total Impurities: ≤1.0%

References

    References

    Hafeez S, Izhar M, Ahmed A, Zafar A, Naeem M (2000) In vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria. J. Pak. Med. Assoc. 50(8):250-252 PMID 10992706

    Kobayashi S, Arai S, Hayashi S and Fujimoto K (1986) β-Lactamase Stability of Cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum. Antimicrob. Agents Chemother. 30(5):713-718 PMID 3492175

    Nikaido H, Liu W and Rosenberg EY (1990) Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34(2):337-342 PMID 2109581

    Rolston KVI, Alvarez ME, Hsu K, Bodey GP (1986) In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients, J. Antimicrob. Chemother. 17(4):453–457

    Rolston K et al (1986) Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients. Chemother. 32(4):344-351

Other Items In This Category